Blog

• 
• 
• 
• 

The U.S. Defense Advanced Research Projects Agency (DARPA) has signed a five-year cooperative agreement worth up to $28 million with Vanderbilt University Medical Center (VUMC) to develop methods for preventing the global spread of viruses like chikungunya and Zika.

Living in an economically disadvantaged neighborhood is likely to lead to death at an earlier age, especially among African-Americans, new research shows. The death rate is even more pronounced among disadvantaged individuals with unhealthy lifestyle habits.

A new study led by Vanderbilt-Ingram Cancer Center (VICC) investigators found that low-income residents in those socioeconomically disadvantaged neighborhoods died much earlier than the average American.

The next installment of the Vanderbilt University School of Medicine’s Enabling Innovations Initiative (eI2) speaker series is set for Friday, February 2nd at 3PM in Light Hall 214.  eI2 is SOM’s new program to promote a culture of innovations and dissemination of new knowledge and discovery through entrepreneurial pathways.  The February 2nd Seminar will feature Dr.

Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, and Vanderbilt-Ingram Cancer Center (VICC) have announced a new collaboration to improve outcomes for cancer patients.

As part of the initial research project, Tempus will use its Tempus O platform to collect and structure clinical data from the cancer center’s electronic health record. Tempus also will provide next generation sequencing and analysis for a subset of patients in order to identify actionable gene alterations.

Vanderbilt University has signed separate licensing and research collaboration agreements with Lundbeck, a global pharmaceutical company based in Denmark, to develop a novel approach for treating schizophrenia.

Under the terms of the licensing agreement, Lundbeck has exclusively licensed rights to compounds developed by the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) that act on a receptor in the brain that has been implicated in schizophrenia.

Blocking a nerve-cell receptor in part of the brain that coordinates movement could improve the treatment of Parkinson’s disease, dyskinesia and other movement disorders, researchers at Vanderbilt University have reported.

Their findings, published recently in the journal Neuron, focus on M4, a subtype of the muscarinic acetylcholine family of nerve cell (neuron) receptors activated by binding the neurotransmitter acetylcholine.

One Vanderbilt Technology earned patent protection

Four new Vanderbilt technologies earn patent protection in November

9,826,904    System and method for detecting tissue surface properties

A team of scientists from Vanderbilt University, led by Professor John Wikswo, have won an R&D 100 Award for their MultiWell MicroFormulator device. The MultiWell MicroFormulator, developed at Vanderbilt and being commercialized by CN Bio Innovations, provides customized realtime formulation, delivery, and removal of cell culture media to each well of a 96-well plate for drug discovery, toxicology research, and personalized medicine.